March 21, 2017 / 11:33 AM / 9 months ago

BRIEF-Apexigen's trial testing APX005M+Keytruda combo starts patient enrollment

March 21 (Reuters) -

* Phase 1/2 clinical trial of Apexigen’s APX005m in combination with Pembrolizumab (keytruda®) opens for metastatic melanoma patients Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below